Gene Mutations Do Not Operate in a Vacuum: the Increasing Importance of Epigenetics in Juvenile Myelomonocytic Leukemia

Overview

Journal Epigenetics

Specialty Genetics

Date 2019 Feb 19

PMID 30773984

Citations 3

Authors

Christian Flotho

Affiliations

Soon will be listed here.

Abstract

Juvenile myelomonocytic leukemia (JMML) stands out among malignant neoplasms of childhood in several ways. First, JMML is a model condition to elucidate the relevance of deregulated Ras signal transduction in human cancer. Second, the identification of Ras pathway mutations in JMML has informed the field of germline cancer predisposition and advanced the understanding of molecular mechanisms underlying the progression from predisposition to neoplasia. Third and not least, genomic DNA methylation was discovered to play a salient role in the classification and prognostication of the disease. This article discusses the evolution of epigenetic research on JMML over the past years and reviews the relevance of aberrant DNA methylation in the diagnosis, concept, and clinical decision-making of JMML.

Citing Articles

BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.

Wu Y, Zehnle P, Rajak J, Koleci N, Andrieux G, Gallego-Villar L Leukemia. 2023; 38(1):136-148.

PMID: 37945692 PMC: 10776398. DOI: 10.1038/s41375-023-02079-5.

Wintering A, Smith S, Fuh B, Rangaswami A, Dahl G, Chien M Pediatr Blood Cancer. 2021; 69(5):e29499.

PMID: 34939322 PMC: 8957526. DOI: 10.1002/pbc.29499.

Juvenile myelomonocytic leukemia presenting in an infant with a subdural hematoma.

Lambert W, DiGiuseppe J, Lara-Ospina T, Bookland M, Martin J, Hersh D Childs Nerv Syst. 2021; 37(6):2075-2079.

PMID: 33404720 DOI: 10.1007/s00381-020-05013-7.

References

Niemeyer C . RAS diseases in children. Haematologica. 2014; 99(11):1653-62. PMC: 4222471. DOI: 10.3324/haematol.2014.114595. View

Olk-Batz C, Poetsch A, Nollke P, Claus R, Zucknick M, Sandrock I . Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011; 117(18):4871-80. DOI: 10.1182/blood-2010-08-298968. View

Bresolin S, De Filippi P, Vendemini F, DAlia M, Zecca M, Meyer L . Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group. Oncotarget. 2016; 7(20):28914-9. PMC: 5045366. DOI: 10.18632/oncotarget.8016. View

Stieglitz E, Taylor-Weiner A, Chang T, Gelston L, Wang Y, Mazor T . The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015; 47(11):1326-1333. PMC: 4626387. DOI: 10.1038/ng.3400. View

Stieglitz E, Mazor T, Olshen A, Geng H, Gelston L, Akutagawa J . Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017; 8(1):2127. PMC: 5736624. DOI: 10.1038/s41467-017-02178-9. View

Wlodarski M, Motter J, Gorr T, Olk-Batz C, Hasle H, Dworzak M . Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood. 2011; 118(16):4490-1. DOI: 10.1182/blood-2011-07-370684. View

Hoyoux C, Dresse M, Forget P, Piette C, Rausin L, Villa A . Osteopetrosis mimicking juvenile myelomonocytic leukemia. Pediatr Int. 2014; 56(5):779-82. DOI: 10.1111/ped.12342. View

Flotho C, Valcamonica S, Schmahl G, Corral L, Ritterbach J, Hasle H . RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999; 13(1):32-7. DOI: 10.1038/sj.leu.2401240. View

Stieglitz E, Liu Y, Emanuel P, Castleberry R, Cooper T, Shannon K . Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood. 2014; 123(9):1426-7. PMC: 3938154. DOI: 10.1182/blood-2013-11-531079. View

10.

Schubbert S, Zenker M, Rowe S, Boll S, Klein C, Bollag G . Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006; 38(3):331-6. DOI: 10.1038/ng1748. View

11.

Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska A, Yoshida N . Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol. 2010; 150(1):83-7. DOI: 10.1111/j.1365-2141.2010.08196.x. View

12.

Cseh A, Niemeyer C, Yoshimi A, Dworzak M, Hasle H, van den Heuvel-Eibrink M . Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood. 2015; 125(14):2311-3. DOI: 10.1182/blood-2015-01-619734. View

13.

MacLeod A, Rouleau J, Szyf M . Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem. 1995; 270(19):11327-37. DOI: 10.1074/jbc.270.19.11327. View

14.

Chan R, Cooper T, Kratz C, Weiss B, Loh M . Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2008; 33(3):355-62. PMC: 2692866. DOI: 10.1016/j.leukres.2008.08.022. View

15.

Inaba T, Honda H, Matsui H . The enigma of monosomy 7. Blood. 2018; 131(26):2891-2898. DOI: 10.1182/blood-2017-12-822262. View

16.

Batz C, Hasle H, Bergstrasser E, van den Heuvel-Eibrink M, Zecca M, Niemeyer C . Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?. Blood. 2010; 115(12):2557-8. DOI: 10.1182/blood-2009-12-260901. View

17.

Furlan I, Batz C, Flotho C, Mohr B, Lubbert M, Suttorp M . Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009; 113(12):2867-8. DOI: 10.1182/blood-2008-12-195693. View

18.

Gazin C, Wajapeyee N, Gobeil S, Virbasius C, Green M . An elaborate pathway required for Ras-mediated epigenetic silencing. Nature. 2007; 449(7165):1073-7. PMC: 2147719. DOI: 10.1038/nature06251. View

19.

Matsuda K, Shimada A, Yoshida N, Ogawa A, Watanabe A, Yajima S . Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007; 109(12):5477-80. DOI: 10.1182/blood-2006-09-046649. View

20.

Tartaglia M, Niemeyer C, Fragale A, Song X, Buechner J, Jung A . Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003; 34(2):148-50. DOI: 10.1038/ng1156. View